MacroGenics, Inc. (MGNX) Stock Forecast
MGNX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.71 / 5 from 7 analysts
- Price target
- $8.00 average of analyst targets
- Upside to target
- +146.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.10
- 52-week range
- $1.33 – $4.86
MGNX analyst ratings
7 analystsNumber of analysts at each rating.
MGNX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MGNX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.17 | −$0.08 | $0.27 | −147.1% | 2 |
| Current fiscal year (2026) | −$1.56 | −$3.20 | −$0.28 | −$1.18 | −32.0% | 7 |
| Next fiscal year (2027) | −$1.47 | −$1.70 | −$1.23 | −$0.74 | −54.0% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MGNX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $39.2M | $10.3M | $62.0M | −46.2% | 5 |
| Current fiscal year (2026) | $108.2M | $65.4M | $148.3M | −27.6% | 6 |
| Next fiscal year (2027) | $90.6M | $26.0M | $155.8M | −16.3% | 5 |
MGNX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MGNX revenue: reported and forecast
MGNX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.31 | −$0.31 | −$0.31 | −$0.27 | −$0.13 | −59.3% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.67 | −$0.67 | −$0.67 | −$1.55 | −$1.56 | +132.3% | 1 up · 3 down |
| Next fiscal year (2027) | −$1.41 | −$1.41 | −$1.41 | −$1.14 | −$1.47 | +3.7% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MGNX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MGNX beat in 5 of 12.
What analysts expect from MGNX
7 analysts cover MacroGenics; their consensus rating is buy (3.71 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.00, 146.2% above the latest close of $3.25. Analysts expect earnings of −$1.56 per share for 2026, −32.0% from a year earlier. For 2027 the average estimate is −$1.47 per share on revenue of $90.6 million. MacroGenics beat the EPS estimate in 5 of the last 12 quarters.
Related: MGNX income statement, MGNX key metrics, MGNX chart. See the MGNX stock overview for the latest quote and news.
MGNX forecast FAQ
What is MacroGenics's price target?
The average analyst price target for MacroGenics is $8.00, 146.2% above the latest close of $3.25.
Is MacroGenics a buy, hold or sell?
Of 7 analysts covering MacroGenics, 2 rate it a strong buy, 1 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MacroGenics's EPS forecast?
Analysts forecast −$1.56 per share for 2026 (range −$3.20 to −$0.28); for 2027 the estimate is −$1.47.
What is MacroGenics's revenue forecast?
The average revenue estimate for 2026 is $108.2 million, growth of −27.6%; for 2027 it is $90.6 million.
When does MacroGenics report earnings?
MacroGenics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.10.
Does MacroGenics usually beat earnings estimates?
MacroGenics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.